Differential effects of paroxetine on fatigue and depression: A randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program
Differential effects of paroxetine on fatigue and depression: A randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program
复制标题
DOI：
10.1200/jco.2003.04.070
复制
发表时间：
2003-12-15
影响因子：
45.3
通讯作者：
King, DK
中科院分区：
文献类型：
--
作者：
Morrow, GR;Hickok, JT;King, DK
目的：疲劳和抑郁通常同时发生在癌症患者中，提示可能基于血清素的共同病因。这项随机临床试验测试是否帕罗西汀，选择性5-羟色胺再摄取抑制剂抗抑郁剂已知调节脑5-羟色胺，将减少癌症患者的疲劳，是否有任何减少是与depression.Patients和方法：癌症患者进行化疗的第一次进行评估疲劳。在第二个化疗周期报告疲劳的704例患者中，549例患者被随机分配接受每日20 mg口服盐酸帕罗西汀或安慰剂治疗8周。在第3和第4周期化疗时进行疲劳和抑郁的评估。结果：共有244例帕罗西汀治疗患者和235例安慰剂治疗患者提供了可评估的数据。两组患者的疲劳程度无差异。在研究结束时，两组的平均抑郁水平存在差异（流行病学研究中心抑郁评分分别为12.0 v14.8，P
Purpose: Fatigue and depression typically occur together in cancer patients, suggesting a common etiology, perhaps based on serotonin. This randomized clinical trial tested whether paroxetine, a selective serotonin reuptake inhibitor antidepressant known to modulate brain serotonin, would reduce fatigue in cancer patients and whether any reduction was related to depression.Patients and Methods: Cancer patients undergoing chemotherapy for the first time were assessed for fatigue. Of 704 patients who reported fatigue at their second chemotherapy cycle, 549 patients were randomly assigned to receive either 20 mg of oral paroxetine hydrochloride daily or placebo for 8 weeks. The assessments of fatigue and depression were performed at cycles 3 and 4 of chemotherapy.Results: A total of 244 patients treated with paroxetine and 235 patients treated with placebo provided assessable data. No difference was detected in fatigue between patient groups. At the end of the study, there was a difference between groups in the mean level of depression (Center for Epidemiologic Studies Depression scores, 12.0 v 14.8, respectively, P